Tag: Recursion

Home Recursion
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Post
April 16, 2024April 16, 2024Uncategorized

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

by

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors Photo of Najat Khan, Ph.D. Najat Khan, Ph.D. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company...

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
Post
January 4, 2024January 4, 2024Uncategorized

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

by

Potential First-in-Class Novel Molecule with Novel Target In-Licensed from Collaboration with Bayer SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from...

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
Post
November 10, 2023November 10, 2023Uncategorized

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

by

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) —  Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with...

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Post
July 12, 2023July 12, 2023Uncategorized

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

by

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as...